P736: Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trialECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1)*;Louis , E.(2);Hisamatsu, T.(3);Jamoul, C.(4);Santermans, E.(4);Harris , K.(5);de Haas, A.(6);Oortwijn , A.(7);Feagan , B.(8);
(1)Hopitaux De Brabois, Department of Gastroenterology and Inserm U954, Vandoeuvre-Lès-Nancy, France;(2)University Hospital of Liège, Department of Gastroenterology, Liege, Belgium;(3)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(4)Galapagos NV, Biostatistics Department, Mechelen, Belgium;(5)Galapagos NV, Medical Evidence Generation Department, Milan, Italy;(6)Galapagos NV, Clinical Development Department, Leiden, The Netherlands;(7)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(8)Western University, Division of Gastroenterology, London- ON, Canada;
P737: Intensification with intravenous ustekinumab in refractory Crohn´s diseaseECCO’23 CopenhagenYear: 2023
Authors: Arroyo Argüelles, J.M.(1);Suárez Ferrer, C.(2)*;Rueda García, J.L.(2);Martín-Arranz, E.(2);Poza Cordón, J.(2);Sánchez-Azofra, M.(2);García-Ramírez, L.(3);Martin-Arranz, M.D.(4);
(1)Hospital Universitario de Jaén, Gastroenterology Department. Hospital Universitario de Jaén- España., Jaén, Spain;(2)Grupo de enfermedades inmunomediadas gastrointestinales y otras patologías digestivas. Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ- Madrid- España., Gastroenterology Department. Hospital Universitario La Paz- Madrid- Spain, Madrid, Spain;(3)Grupo de enfermedades inmunomediadas gastrointestinales y otras patologías digestivas. Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ- Madrid- España., Fundación para la Investigación Biomédica- Hospital Universitario La Paz- Madrid- Spain, Madrid, Spain;(4)Grupo de enfermedades inmunomediadas gastrointestinales y otras patologías digestivas. Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ- Madrid- España., Gastroenterology Department. Hospital Universitario La Paz- Madrid- Spain. Faculty of Medicine. Universidad Autónoma de Madrid, Madrid, Spain;
P738: Surgery for Crohn's Disease: Results from a Spanish cohort with 15 years of follow-upECCO’23 CopenhagenYear: 2023
Authors: Elosua Gonzalez, A.(1)*;Rubio, S.(2);Irisarri, R.(2);Campillo, A.(3);Nantes, Ó.(2);Vicuña, M.(2);Angós, R.(4);Zozaya, J.M.(2);Rodríguez, C.(2);
(1)Hospital García Orcoyen, Gastroenterology, Estella, Spain;(2)Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain;(3)Hospital Reina Sofía, Gastroenterology, Tudela, Spain;(4)Clínica Universidad de Navarra, Gastroenterology, Pamplona, Spain;
P739: Sequential treatment is effective to achieve remission and avoid colectomy in moderate-to-severe Ulcerative Colitis refractory to anti-TNF therapyECCO’23 CopenhagenYear: 2023
Authors: Farkas, B.(1)*;Borsos, M.(2);Resál, T.(1);Bacsur, P.(1);Bor, R.(1);Bálint, A.(1);Fábián, A.(1);Szepes, Z.(1);Molnár, T.(1);Farkas, K.(1);
(1)Albert Szent-Györgyi Medical School- University of Szeged, Department of Internal Medicine, Szeged, Hungary;(2)AdWare Research, Department of Biostatistics, Balatonfüred, Hungary;
P740: Dual biologic therapy for patients with Inflammatory Bowel Disease in a single reference center in SpainECCO’23 CopenhagenYear: 2023
Authors: Diz Lois Palomares, M.T.(1)*;Porta Sánchez, Á.(2);González Conde, B.(1);Estévez Prieto, E.(1);Vázquez Rey, M.T.(1);Elberdin Pazos, L.(2);Alonso Aguirre, P.(1);Martin Herranz, I.(2);
(1)A Coruña Universitary Hospital, Gastroenterology, A Coruña, Spain;(2)A Coruña Universitary Hospital, Pharmacy Department, A Coruña, Spain;
P742: Real-world evidence comparison on the effectiveness of ustekinumab vs anti-TNF or vedolizumab in ulcerative colitis: induction phase results from the prospective, observational RUN-UC studyECCO’23 CopenhagenYear: 2023
Authors: Bokemeyer, B.(1,2,3)*;Plachta-Danielzek, S.(2);Howaldt, S.(4);Mohl, W.(5);Efken, P.(6);Ehehalt, R.(7);Kahl, M.(8);Krause, T.(9);Trentmann, L.(10);Lügering, A.(11);Schnoy, E.(12);Jochum, C.(13);Fajardo Salmon, S.(2);Hartmann, P.(6);Gilman, E.(2);Schreiber, S.(2,3);
(1)Prof. Dr. Bernd Bokemeyer, Interdisciplinary Crohn Colitis Centre Minden, Minden, Germany;(2)Competence Network IBD, Study Department, Kiel, Germany;(3)University Hospital Schleswig-Holstein Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;(4)Research Institut for IBD-HaFCED Hamburg, Gastroenterology Practice, Hamburg, Germany;(5)Center for Gastroenterology Saar MVZ, Gastroenmterology, Saarbruecken, Germany;(6)Gastroenterology Practice Minden, Gastroenterology, Minden, Germany;(7)Gastroenterology Practice Heidelberg, Gastroenterology, Heidelberg, Germany;(8)Gastroenterology Practice Hamburg, Gastroenterology, Hamburg, Germany;(9)Gastroenterology Practice Kassel, Gastroenterology, Kassel, Germany;(10)Gastroenterology Practice Bremen, Gastroenterology, Bremen, Germany;(11)Center for Gastroenterology Portal 10 Münster MVZ, Gastroenterology, Münster, Germany;(12)University Hospital Augsburg, III. Medical Clinic - Gastroenterology, Augsburg, Germany;(13)University Hospital Charite Berlin- Campus Mitte, Department of Hepatology and Gastroenterology, Berlin, Germany;
P743: Relative association of bowel urgency improvement versus remission of stool frequency and rectal bleeding with Patient Global Rating of Severity or Change scores in moderately-to-severely active Ulcerative Colitis: An analysis from the LUCENT-1 and LUCENT-2 Phase 3 trialsECCO’23 CopenhagenYear: 2023
Authors: Travis, S.(1)*;Wu, J.(2);Keohane, A.(2);Gibble, T.H.(2);Hibi, T.(3);
(1)Oxford University, Gastroenterology, Oxford, United Kingdom;(2)Eli Lilly and Company, Immunology, Indianapolis, United States;(3)Kitasato Institute Hospital Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan;
P744: Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeedingECCO’23 CopenhagenYear: 2023
Authors: Chaparro, M.(1)*;García Donday, M.(1);Rubio, S.(2);Calviño Suarez, C.(3); Nuñez Ortiz, A.(4);Figueira, M.(5);Marín Pedrosa, S.(6);Rivero, M.(7); Fernández-Clotet, A.(8);Madero, L.(9);Diz-Lois Palomares, M.T.(10);Pérez-Martínez, I.(11);Ruiz-Cerulla, A.(12);Arroyo, M.(13);Piqueras, M.(14); Suarez Ferrer, C.(15);Aguas, M.(16);Calvo Moya, M.(17);Guerra, I.(18); López Serrano, P.(19);Vázquez Morón, J.M.(20);Arias García, L.(21);Casanova, M.J.(1);Huguet, J.M.(22);Valldosera Gomis, G.(23);Zúñiga de Mora-Figueroa, B.(24);Armesto, R.(25);Martínez Montiel, P.(26);Rodríguez-Lago, I.(27);Sendra Rumbeu, P.(28);Camargo Camero, R.(29);Hervías Cruz, D.(30);Molina Arriero, G.(31);Barreiro-de Acosta, M.(3);Acosta, D.(1);Brenes, Y.(1);Hermida, S.(1);Parra, P.(1);Garre, A.(1);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- IIS-Princesa- Universidad Autónoma de Madrid UAM- and CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario de Navarra, Gastroenterology Unit, Pamplona, Spain;(3)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(4)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(5)Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación de Patología Digestiva. IS Galicia Sur. SERGAS UVIGO, Gastroenterology Unit, Vigo, Spain;(6)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(7)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology Unit, Santander, Spain;(8)Hospital Universitario Clìnic i Provincial, Gastroenterology Unit, Barcelona, Spain;(9)Hospital General Universitario de Alicante, Gastroenterology Unit, Alicante, Spain;(10)Complexo Hospitalario Universitario de A Coruña, Gastroenterology Unit, A Coruña, Spain;(11)Hospital Universitario Central de Asturias and ISPA, Gastroenterology Unit, Oviedo, Spain;(12)Hospital Universitario de Bellvitge, Gastroenterology Unit, Barcelona, Spain;(13)Hospital Clínico Universitario Lozano Blesa- IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(14)Consorci Sanitari de Terrassa CST, Gastroenterology Unit, Barcelona, Spain;(15)Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain;(16)Hospital Universitario y Politécnico La Fe and CIBEREHD, Gastroenterology Unit, Valencia, Spain;(17)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain;(18)Hospital Universitario de Fuenlabrada and IdiPAZ, Gastroenterology Unit, Madrid, Spain;(19)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(20)Hospital Universitario Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain;(21)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(22)Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(23)Hospital Universitario Joan XXIII, Gastroenterology Unit, Tarragona, Spain;(24)Hospital Clínico Universitario San Cecilio, Gastroenterology Unit, Granada, Spain;(25)Complexo Hospitalario Universitario de Ourense, Gastroenterology Unit, Ourense, Spain;(26)Hospital Universitario 12 de Octubre, Gastroenterology Unit, Madrid, Spain;(27)Hospital Universitario de Galdakao- Instituto de Investigación Sanitaria Biocruces Bizkaia, Gastroenterology Unit, Galdakao, Spain;(28)Hospital Universitario Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(29)Hospital Universitario Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain;(30)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(31)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, Ferrol, Spain;on behalf of DUMBO study group of GETECCU
P745: Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohortECCO’23 CopenhagenYear: 2023
Authors: Gros, B.(1,2)*;Plevris, N.(1);Constantine-Cooke, N.(3,4);Lyons, M.(1);O'Hare, C.(1,5);Noble, C.(1);Arnott, I.D.(1);Jones, G.R.(1,6);Lees, C.W.(1,4);Derikx, L.A.A.P.(1,7,8);
(1)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Reina Sofía University Hospital, Gastroenterology and hepatology department, Cordoba, Spain;(3)Institute of Genetics and Cancer- University of Edinburgh, MRC Human Genetics Unit-, Edinburgh, United Kingdom;(4)Institute of Genetics and Cancer- University of Edinburgh, Centre for Genomics and Experimental Medicine, Edinburgh, United Kingdom;(5)Western General Hospital, Edinburgh Pharmacy Unit, Edinburgh, United Kingdom;(6)The Queen's Medical Research Institute- University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom;(7)Erasmus MC- University Medical Centre Rotterdam, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(8)Department of Gastroenterology and Hepatology- Radboud University Medical Center, Inflammatory Bowel Disease Center, Nijmegen, The Netherlands;
P746: Identification of Altered Microbial Genera at Baseline in Adalimumab Clinical Remitters and an Absence of Change in Total Microbial Composition Post Induction Treatment in the SERENE UC StudyECCO’23 CopenhagenYear: 2023
Authors: Morsy, Y.(1);Pivorunas, V.(2);Leitner, C.(3);Birchler, T.(4);Guay, H.(2);Scharl, M.(1)*;
(1)University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;(2)AbbVie Bioresearch Centre, Precision Medicine Immunology, Worcester, United States;(3)AbbVie AG, Gastroenterology, Cham, Switzerland;(4)AbbVie AG, Immunology, Cham, Switzerland;
P747: The impact of COVID-19 on patients with Inflammatory Bowel Disease: A population-based study using artificial intelligence.ECCO’23 CopenhagenYear: 2023
Authors: Moralejo Lozano, Ó.(1)*;Beneyto Martín, P.(2);Abanades Tercero, M.(1);Muñoz Rosas, C.(1);Ruano Díaz, L.(1);Salmoral Luque, R.(1);Gómez Rodríguez, R.(1);
(1)Hospital Universitario de Toledo, Gastroenterology and Hepatology Aparato Digestivo, Toledo, Spain;(2)Hospital Universitario de Toledo, Research Department, Toledo, Spain;
P748: Pharmacokinetics, relative bioavailability, and dose proportionality of a tablet formulation of the sphingosine 1-phosphate-1 receptor modulator VTX002 (formerly OPL-002)ECCO’23 CopenhagenYear: 2023
Authors: Gregg, R.(1);Yun, C.(1)*;Naik, S.(1);Huyghe, M.(2);Harris, J.(2);Mohan, R.(1);Nuss, J.(1);Sandborn, W.J.(1);
(1)Ventyx Biosciences, Clinical Development, Encinitas, United States;(2)Former employee of Oppilan Pharma acquired by Ventyx Biosciences, Clinical Development, Encinitas, United States;
P749: Crohn's disease stricture response and resolution with adalimumab therapy demonstrated with intestinal ultrasound. The STRIDENT randomised trial.ECCO’23 CopenhagenYear: 2023
Authors: Lovett, G.(1,2)*;Schulberg, J.D.(1,2);Hamilton, A.L.(1,2);Wright, E.K.(1,2);Sutherland, T.R.(2,3);Kamm, M.A.(1,2);
(1)St Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine, Melbourne, Australia;(3)St Vincent's Hospital Melbourne, Department of Radiology, Melbourne, Australia;
P750: Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Hou, J.K.(1)*;Pham, C.(2);Sansgiry, S.(3);Modi, V.(2);Waljee, A.K.(4);
(1)Baylor College of Medicine 5207 Contour Place, Section of Gastroenterology, Houston, United States;(2)Baylor College of Medicine, Medicine, Houston, United States;(3)Baylor College of Medicine- Michael E. DeBakey VA Medical Center, Medicine, Houston, United States;(4)Ann Arbor VA- University of Michigan, Medicine, Ann Arbor- VA, United States;
P752: Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Abraham, B.(2);Bressler, B.(3);Reinisch, W.(4);Axelrad, J.E.(5);Jain, A.(6);Memaj, A.(6);Akukwe, L.(6);Liu, W.J.(6);Osterman, M.T.(6);Canavan, J.B.(6);Sands, B.E.(7);
(1)University of Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(2)Houston Methodist-Weill Cornell Medical, Gastroenterology, Cornell, United States;(3)University of British Columbia, Medicine, Vancouver, Canada;(4)Medical University of Vienna, Gastroenterology and Hepatology, Vienna, Austria;(5)NYU Grossman School of Medicine, Medicine, New York, United States;(6)Bristol Myers Squibb, Clinical Research, Princeton, United States;(7)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;
P753: Comparing long-term outcomes in inflammatory bowel disease patients between switch and non-switch cohorts: no differences in infliximab persistence or safety outcomes after 54 monthsECCO’23 CopenhagenYear: 2023
Authors: Suo, P.(1)*;Thin, L.(2);Srinivasan, A.(3);Winston, J.(4);Jeffrey, A.(5);Menon, S.(5);Ghaly, S.(6);Haifer, C.(7);
(1)St Vincent's Hospital, Department of Gastroenterology, Sydney, Australia;(2)Fiona Stanley Hospital- University of Western Australia, Department of Gastroenterology, Perth, Australia;(3)Eastern Health- University of Melbourne, Department of Gastroenterology, Melbourne, Australia;(4)Eastern Health, Department of Gastroenterology, Melbourne, Australia;(5)Royal Perth Hospital, Department of Gastroenterology, Perth, Australia;(6)St Vincent's Hospital- St Vincent's Clinical School- UNSW Sydney, Department of Gastroenterology, Sydney, Australia;(7)St Vincent's Hospital- St Vincent's Private Hospital, Department of Gastroenterology, Sydney, Australia;
P755: Impaired antibody seroconversion after COVID-19 vaccination and negative impact of immunosuppressive treatment in Inflammatory Bowel Disease. Results from a multicentre, prospective study of GETECCU (VACOVEII).ECCO’23 CopenhagenYear: 2023
Authors: Julián, A.B.(1)*;Casas-Deza, D.(1);Vicente-Lidón, R.(1);Beltrán, B.(2);Domènech, E.(3);Gutiérrez-Casbas, A.(4,5);Mañosa, M.(3);Zabana, Y.(5,6);Caudevilla-Biota, E.(7);Corsino-Roche, P.(1,7);Sierra-Moros, E.(1);Franco-Fobe, L.E.(8);Pina-Echevarría, S.(8);García-González, E.(9);Alfambra, E.(7,10);Gargallo-Pueyo, C.(7,10);Sicilia, B.(11);Arias, L.(11);Alcala-Escriche, M.J.(12);Madero-Velázquez, L.(4);Ferreiro-Iglesias, R.(13);Palmero-Pérez, A.(14);Calafat, M.(3,5);Rubio-Iturria, S.(15);Moraleja-Yudego, I.(16);Ber-Nieto, Y.(17);García-Mateo, S.(10);P. Gisbert, J.(5,18,19);Barreiro-de Acosta, M.(13);García-López, S.(1,7);
(1)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(2)Hospital Universitari i Politècnic La Fe, Gastroenterology, Valencia, Spain;(3)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(4)Hospital General Universitario Doctor Balmis, Gastroenterology, Alicante, Spain;(5)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Gastroenterology, Madrid, Spain;(6)Hospital Universitari Mútua Terrassa, Gastroenterology, Tarrassa, Spain;(7)Instituto de Investigación Sanitaria de Aragón, Gastroenterology, Zaragoza, Spain;(8)Hospital Universitario Miguel Servet, Microbiology, Zaragoza, Spain;(9)Hospital Universitario Miguel Servet, Biochemistry, Zaragoza, Spain;(10)Hospital Clínico Lozano Blesa, Gastroenterology, Zaragoza, Spain;(11)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(12)Hospital Obispo Polanco, Gastroenterology, Teruel, Spain;(13)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain;(14)Hospital Royo Villanova, Gastroenterology, Zaragoza, Spain;(15)Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain;(16)Hospital de Galdakao-Usansolo, Gastroenterology, Galdakao, Spain;(17)Hospital San Jorge, Gastroenterology, Huesca, Spain;(18)Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain;(19)Instituto de Investigación Sanitaria Princesa, Gastroenterology, Madrid, Spain;GETECCU
